NAVLE Hemic and Lymphatic

Equine Piroplasmosis Study Guide

📅 March 28, 2026 ⏱ 25 min read

Equine piroplasmosis (EP) is a tick-borne, hemoprotozoan disease of equids caused by the intraerythrocytic apicomplexan parasites Theileria equi and Babesia caballi.

Overview and Clinical Importance

Equine piroplasmosis (EP) is a tick-borne, hemoprotozoan disease of equids caused by the intraerythrocytic apicomplexan parasites Theileria equi and Babesia caballi. A third species, Theileria haneyi, has recently been identified but appears to have lower pathogenicity. EP is a WOAH (formerly OIE) reportable disease that affects horses, donkeys, mules, and zebras worldwide.

This disease has significant economic impact due to treatment costs, restrictions on international horse movement, reduced performance in sport horses, and potential mortality rates of 5-10% in endemic areas and up to 50% in naive animals imported to endemic regions.

High-YieldThe United States is considered free of natural tick-borne transmission of EP (except Puerto Rico and U.S. Virgin Islands). EP is a foreign animal disease in the U.S. and all positive cases MUST be reported to State and Federal animal health officials.

Feature	Theileria equi	Babesia caballi
Previous Name	Babesia equi	Piroplasma caballi
Size	Smaller (2-3 micrometers)	Larger (2-5 micrometers)
Blood Smear Morphology	Maltese cross (tetrad), ring forms, paired pyriform	Paired pyriform (pear-shaped), connected at acute angle
Extra-RBC Stage	Yes - schizogony in lymphocytes and monocytes	No - directly infects erythrocytes
Transovarial Transmission	No (transstadial only)	Yes (tick is reservoir)
Primary Reservoir	Equine host (lifelong carrier)	Tick vector
Carrier Duration	Lifelong without treatment	Self-limiting (up to 4 years)
Relative Pathogenicity	More pathogenic and severe	Generally milder disease
Parasitemia Level	1-7% of erythrocytes	0.1-1% of erythrocytes
Treatment Response	Difficult to clear; higher doses needed	Easier to eliminate

Etiology and Causative Agents

Equine piroplasmosis is caused by two primary hemoprotozoan parasites within the phylum Apicomplexa and order Piroplasmida. The term "piroplasmosis" derives from the pear-shaped (pyriform) appearance of the intraerythrocytic merozoite stage.

Comparison of Causative Agents

NAVLE TipThe MALTESE CROSS (tetrad formation) is PATHOGNOMONIC for Theileria equi on blood smear - this distinguishes it from B. caballi which shows PAIRED PYRIFORM organisms. Remember: "T for Tetrad, T for Theileria."

Form	Clinical Presentation
Peracute	Rare. Animals found moribund or dead. Most common in neonatal piroplasmosis or naive adults exposed to high doses. Mortality can exceed 50%.
Acute	Most common clinical form. Fever greater than 40°C (104°F), anorexia, depression, tachycardia, tachypnea, pale or icteric mucous membranes, petechiae, hemoglobinuria (dark red-brown urine), bilirubinuria, peripheral edema, splenomegaly.
Subacute	Similar to acute but milder clinical signs. Intermittent fever, mild anemia, mild icterus, weight loss.
Chronic	Nonspecific signs: mild inappetence, poor exercise tolerance, weight loss, transient fever, enlarged spleen on rectal exam. Minimal or no anemia. May be subclinical.
Carrier (Subclinical)	Asymptomatic. Persistent infection without clinical signs. Common in endemic areas. Horses serve as reservoir for tick infection.

Epidemiology

Geographic Distribution

EP is endemic in approximately 90% of the world where competent tick vectors are present, including tropical, subtropical, and some temperate regions. Endemic areas include South and Central America, the Caribbean, Africa, the Middle East, Asia, and Southern and Eastern Europe.

Non-endemic areas: United States (mainland), Canada, United Kingdom, Ireland, Northern Europe, Iceland, Greenland, Singapore, Japan, New Zealand, and Australia.

High-YieldT. equi is more prevalent globally than B. caballi. The global seroprevalence of T. equi is approximately 33%, while B. caballi is approximately 20%. South America (particularly Brazil) has the highest reported prevalence of both parasites.

Transmission and Tick Vectors

Over 30 species of ixodid ticks have been identified as vectors for EP parasites. The primary tick genera involved include:

Dermacentor spp. (including D. variabilis - American dog tick, D. nitens - tropical horse tick)
Rhipicephalus spp. (including R. microplus - cattle fever tick)
Hyalomma spp.
Amblyomma spp. (including A. cajennense - cayenne tick)
Haemaphysalis spp.

Routes of Transmission

Tick-borne (biological): Primary route. Both parasites transmitted transstadially; only B. caballi transmitted transovarially.
Iatrogenic: Via contaminated needles, syringes, surgical instruments, dental equipment, or blood transfusions.
Transplacental (vertical): Documented for T. equi. Can cause abortion, stillbirth, or neonatal piroplasmosis.

NAVLE TipIn recent U.S. outbreaks, iatrogenic transmission (especially reuse of needles and syringes) has been the most common route of transmission - NOT tick-borne! Always use sterile, single-use equipment.

Test	Best Use	Advantages	Limitations
Blood Smear	Acute clinical cases	Rapid, inexpensive, specific when positive. Can identify morphology.	Low sensitivity. Often negative in chronic/carrier states. Parasitemia may be very low.
cELISA	Carrier detection, export testing. GOLD STANDARD for chronic cases.	Most sensitive for chronic infections. Detects antibodies 21 days post-infection. Standardized.	Antibodies persist 6-24 months after clearance. Cannot confirm active infection.
CFT	Acute infection detection	Detects seroconversion 8-11 days post-infection. Very specific.	Low sensitivity for chronic cases. IgG(T) is not complement-fixing.
IFAT	Confirmatory test. Detects 3-20 days post-infection.	Good sensitivity. Remains positive in chronic cases.	Subjective interpretation. Requires skilled personnel.
PCR	Confirming active infection. Most sensitive for parasite detection.	Highest sensitivity (10^-7% parasitemia). Confirms current infection. Species differentiation.	More expensive. Not standardized between labs. Not currently required for export.

Clinical Signs and Presentation

Incubation Period: T. equi: 12-19 days; B. caballi: 10-30 days. Incubation is highly variable with iatrogenic transmission and may be dose-dependent.

Clinical signs result primarily from intravascular hemolytic anemia caused by parasite replication within and destruction of erythrocytes. T. equi infection typically causes more severe disease than B. caballi.

Clinical Forms of Piroplasmosis

"PIRO-PLASMA" Mnemonic: P - Pyrexia (fever greater than 40°C) I - Icterus (jaundice) R - Red/dark urine (hemoglobinuria) O - Organ enlargement (splenomegaly, hepatomegaly) P - Pale mucous membranes (anemia) L - Lethargy and depression A - Anorexia S - Sweating M - Mucosal petechiae A - Accelerated heart and respiratory rates

Goal	Species	Imidocarb Dose	Regimen
Clinical Suppression	Either species	2.2-2.4 mg/kg IM	Single dose
Parasite Clearance	B. caballi	2.2 mg/kg IM	2 doses, 24 hours apart
Parasite Clearance	T. equi	4.0 mg/kg IM	4 doses, 72 hours apart

Diagnosis

Diagnosis relies on a combination of clinical signs, hematologic findings, and specific diagnostic tests. No single test is ideal for all situations.

Diagnostic Methods Comparison

High-YieldFor international export, the cELISA is the WOAH-recommended test for detecting carrier horses. The CFT may also be required. For clinical diagnosis of acute disease, combine blood smear examination with paired serology (CFT or IFAT). A positive PCR confirms active infection, but serology can remain positive 6-24 months after parasite clearance.

Treatment

Imidocarb dipropionate is the drug of choice for equine piroplasmosis. Treatment protocols differ based on the goal (clinical improvement vs. parasite clearance) and the causative species.

Treatment Protocols

Managing Imidocarb Side Effects

Imidocarb has anticholinesterase activity that causes significant adverse effects including colic, diarrhea, excessive salivation, lacrimation, and increased borborygmi.

Glycopyrrolate 0.0025 mg/kg IV - Preferred premedication. Reduces GI side effects without significantly affecting GI motility.
Atropine 0.035 mg/kg IV - Alternative but may cause ileus.
N-butylscopolammonium (Buscopan) 0.3 mg/kg IV - Counteracts anticholinesterase effects.
Flunixin meglumine - For pain and inflammation.

High-YieldThe 4 mg/kg dose for T. equi clearance approaches the LD50 for imidocarb and carries significant risk of hepatotoxicity and nephrotoxicity. Donkeys and mules are MORE SENSITIVE to imidocarb toxicity than horses. Monitor renal and hepatic function during high-dose treatment. Injection site reactions are common.

Supportive Care

Fluid therapy: Essential to maintain renal perfusion and prevent pigment nephropathy from hemoglobinuria.
Blood transfusion: Indicated if PCV falls below 12-16%. Screen donors for EP before use!
NSAIDs: Flunixin meglumine for antipyretic and analgesic effects.
Nutritional support: Address hyperlipemia if present (especially in donkeys and ponies).

Prognosis and Prevention

Prognosis

Endemic areas: Mortality 5-10% with treatment. Most horses develop premonition (carrier immunity).
Naive animals: Mortality may exceed 50% without prompt treatment.
Neonatal piroplasmosis: Poor prognosis. Often rapidly fatal.
Carrier status: T. equi carriers persist lifelong without treatment. B. caballi may self-clear in up to 4 years.

Prevention and Control

Tick control: Strategic acaricide use. Environmental management. Regular tick checks.
Biosecurity: Single-use needles and equipment. Screen blood donors. Quarantine new arrivals.
Import testing: cELISA and CFT required for international movement to non-endemic countries.
Vaccination: No commercially available vaccines currently exist.

NAVLE TipIn endemic areas, the goal is often to maintain PREMONITION (carrier immunity) rather than eliminate the parasite. Naive adult horses introduced to endemic areas are at highest risk for severe clinical disease. In non-endemic areas, the goal is COMPLETE PARASITE CLEARANCE and prevention of introduction.

Differential Diagnosis

When evaluating a horse with fever, anemia, and icterus, consider these differentials:

Equine Infectious Anemia (EIA): Retroviral disease. Coggins test positive. No treatment.
Immune-mediated hemolytic anemia (IMHA): Coombs test positive. Responds to immunosuppression.
Neonatal isoerythrolysis: Foals nursing incompatible colostrum. Direct Coombs positive.
Equine granulocytic anaplasmosis: Anaplasma phagocytophilum. Morulae in neutrophils.
Red maple toxicosis: Heinz body hemolytic anemia. History of access to wilted leaves.
Hepatic disease: Elevated liver enzymes. Icterus from hepatic dysfunction.
African horse sickness: Orbivirus. Geographic restriction. Severe respiratory and cardiac forms.

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →